Search

Author/Creator Overmoyer, Beth

1. A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance). Issue 3 (1st November 2018)

Authors:
Rashkin, Sara R.; Chua, Katherina C.; Ho, Carol; Mulkey, Flora; Jiang, Chen; Mushiroda, Tasei; Kubo, Michiaki; Friedman, Paula N.; Rugo, Hope S.; McLeod, Howard L.; Ratain, Mark J.; Castillos, Francisco; Naughton, Michael; Overmoyer, Beth; Toppmeyer, Deborah; Witte, John S.; Owzar, Kouros; Kroetz...
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 105:Issue 3(2019)
Page Start:
738
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. (12th November 2021)

Authors:
Strickland, Matthew; Lee, Eudocia Quant; Wang, Nancy; Cohen, Justine; Chukwueke, Ugonma; Forst, Deborah; Eichler, April; Overmoyer, Beth; Lin, Nancy; Chen, Wendy; Bardia, Aditya; Juric, Dejan; Dagogo-Jack, Ibiayi; White, Michael; Dietrich, Jorg; Nayyar, Naema; Kim, Albert; Alvarez-Breckenridge, C...
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 6(2021)
Page Start:
vi49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. (July 2022)

Authors:
Pernas, Sonia; Guerriero, Jennifer L.; Naumenko, Sergey; Goel, Shom; Regan, Meredith M.; Hu, Jiani; Harrison, Beth T.; Lynce, Filipa; Lin, Nancy U.; Partridge, Ann; Morikawa, Aki; Hutchinson, John; Mittendorf, Elizabeth A.; Sokolov, Artem; Overmoyer, Beth
Journal:
Therapeutic advances in medical oncology
Issue:
Volume 14(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana‐Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Issue 3 (25th August 2019)

Authors:
Nakhlis, Faina; Regan, Meredith M.; Chun, Yoon S.; Dominici, Laura S.; Caterson, Stephanie; Bellon, Jennifer R.; Warren, Laura; Yeh, Eren D.; Jacene, Heather A.; King, Tari A.; Overmoyer, Beth
Journal:
Breast journal
Issue:
Volume 26:Issue 3(2020)
Page Start:
384
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). (4th December 2019)

Authors:
Sharma, Manish R.; Mehrotra, Shailly; Gray, Elizabeth; Wu, Kehua; Barry, William T.; Hudis, Clifford; Winer, Eric P.; Lyss, Alan P.; Toppmeyer, Deborah L.; Moreno‐Aspitia, Alvaro; Lad, Thomas E.; Velasco, Mario; Overmoyer, Beth; Rugo, Hope S.; Ratain, Mark J.; Gobburu, Jogarao V.
Journal:
Journal of clinical pharmacology
Issue:
Volume 60:Number 4(2020)
Page Start:
444
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Issue 10 (17th October 2022)

Authors:
Waks, Adrienne G; Keenan, Tanya E; Li, Tianyu; Tayob, Nabihah; Wulf, Gerburg M; Richardson, Edward T; Attaya, Victoria; Anderson, Leilani; Mittendorf, Elizabeth A; Overmoyer, Beth; Winer, Eric P; Krop, Ian E; Agudo, Judith; Van Allen, Eliezer M; Tolaney, Sara M
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗